CompanyDeals

BD and Ypsomed Develop Neopak XtraFlow 5.5mL Prefilled Syringe for YpsoMate Auto‑Injector

CompanyDeals

Syngene Extends BMS Partnership to 2035, Expanding CRDMO Services

CompanyDrug

Hengrui Pharma’s SHR‑7877 Gets NMPA Nod for Small Cell Lung Cancer Trials

CompanyDeals

PrimeGenX Therapeutics Files for Hong Kong IPO with JAK‑STAT Pipeline

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth
Company

J&J Reports $94.2 Billion Full‑Year 2025 Revenue, Driven by Oncology and Immunology Growth

CompanyDrug

AbbVie Secures Second China Approval for Risankizumab in Ulcerative Colitis

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio
CompanyDeals

Bio‑Sincerity Pharma‑Tech Secures Greater China Priority Rights for Delim’s Semaglutide and Tirzepatide Portfolio

CompanyDeals

TaiGen and Joincare Partner on TG‑4318 DPP1 Inhibitor for Bronchiectasis in Greater China

CompanyDeals

China Isotope & Radiation Corporation Signs Commercial Deal for Pluvicto, China’s First PSMA Radioligand Therapy

CompanyDeals

Matwings Technology Partners with Leading US Biotech on AIACCLBIO Platform for Biopharmaceutical Pipeline

CompanyDeals

AmCellGene Licenses Mesenchymal Stem Cell Therapy for ACLF to Advanced Regeneration in First Chinese Stem Cell Outbound Deal

CompanyDeals

Huadong Medicine Secures Exclusive China Commercialization Rights for Linaprazan Glurate P‑CAB from Sinorda